Project Details
Description
A Phase 1b Randomized, Double Blinded, Placebo Controlled, Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Doses of ARCT-810 in Clinically Stable Patients with Ornithine Transcarbamylase Deficiency
| Status | Active |
|---|---|
| Effective start/end date | 6/1/20 → 6/30/25 |
Funding
- ARCTURUS THERAPEUTICS, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.